DUBLIN, Ireland, Jan. 04, 2017 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the 35th Annual J.P. Morgan Healthcare Conference on January 12th at 11:00 AM PT in San Francisco, CA.
A live webcast of the company presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena is establishing a fully integrated research, development and commercial focus and has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's website at www.prothena.com.
Contacts Investors: Tran Nguyen, CFO 650-837-8535, [email protected] Media: Ellen Rose 650-922-2405, [email protected]


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Washington Post Publisher Will Lewis Steps Down After Layoffs
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



